Off-Label Use Of Zometa For Osteoporosis Accounts For 5% Of Sales

Novartis sees growth of Zometa in oncology despite financial incentives to prescribe generic bisphosphonates, North American Oncology Head Dunshire says. The company is on track to submit a once-yearly formulation of zoledronic acid for osteoporosis in 2007.